Gaining Control of Eosinophilic Disorders

Join us on Sunday, May 17, 2026, in Orlando, FL or via live stream! Click below for more information and to register.

There is no registration fee for attending this CME symposium; however, space is limited. Preregistration does not guarantee entry. We recommend arriving at the meeting room early.

Program Overview

Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are both rare types of eosinophilic disorders. Diagnosis and management of these disorders is challenging due to their complex and overlapping pathologic features and heterogeneous systemic involvement. Both disorders carry substantial risks of morbidity and mortality due to delayed diagnosis and inadequate treatment. Interleukin (IL)-5 is a key driver of pathophysiology; therapies targeting IL-5 or the IL-5 receptor are a mainstay of treatment. In this confidence-based clinical decision CALIBRATE™ symposium, Drs. Praveen Akuthota, Philip Seo, and Michael Wechsler will discuss EGPA and HES patient cases with real-world, point-of-care decision checkpoints paired with confidence ratings to improve diagnosis and treatment sequencing.

Target Audience

This program is designed to educate pulmonologists, rheumatologists, clinical immunologists/allergists, hematologists, and other specialists who identify and manage patients with hypereosinophilic syndrome (HES) or eosinophilic granulomatosis with polyangiitis (EGPA).

Educational Objectives

After completing this activity, the participant should be better able to:

• Discuss the burdens of EGPA and HES with a focus on the effects of delayed diagnosis and suboptimal treatment
• Diagnose EGPA or HES promptly based on symptomology, red flags, medical history, ancillary testing, and appropriate multidisciplinary collaboration
• Describe the mechanistic rationale and trial evidence for biologic therapies for patients with EGPA or HES
• Construct biologic-based treatment regimens for EGPA or HES that optimize disease control, minimize corticosteroid use, and target long-term remission